221. 抗糸球体基底膜腎炎 Anti-glomerular basement membrane disease Clinical trials / Disease details
臨床試験数 : 1 / 薬物数 : 3 - (DrugBank : 1) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03157037 (ClinicalTrials.gov) | March 1, 2017 | 11/5/2017 | An Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease (GOOD-IDES) | An Open-Label Phase II Study in Anti-GBM Disease (Goodpasture's Disease) With Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS --GOOD-IDES | Anti-Glomerular Basement Membrane Disease | Biological: HMed-IdeS | Mårten Segelmark | Hansa Biopharma AB | Completed | 18 Years | N/A | All | 15 | Phase 2 | Austria;Czechia;Denmark;France;Sweden |